Today’s demand for access to experimental agents requires sponsors to address complex challenges that shape the approval, use, and price of their best products. Often confusing realities include uncertain costs for program infrastructure, especially in early stage companies; a lack of systems for access; no knowledge of common pitfalls or an understanding of industry best practices as well as ethical concerns about allocation of limited drug supply. Regulatory frameworks vary by country, if they exist at all, and other drug distribution initiatives, e.g., patient assistance programs and philanthropic efforts, may be misaligned. Potential damage to corporate reputation is significant and media interest is great.
Our customized services will help ensure you offer a responsible early access program if and when appropriate.
To help a company maximize the benefit of conducting an advocacy-focused patient journey map, VOZ also offers.
Unbiased examination of the need for compassionate use, expanded access or other compliant mechanisms.
Determination of appropriate goals and best approaches to meeting patients’ legitimate medical needs.
Opportunities to ensure the company tackles early access in a unified, consistent fashion.
Consultation with the nation’s most respected ethicists about difficult issues.
Statements that ensure internal and, if needed, external understanding of the company’s unique approach to early access.
Detailed blueprints for program execution, including vetting of program partners, costs, and timelines.
Practical guidance and assistance that helps patients in need.
Identification and training in the appropriate response to potential crises.